AI and MRD Take Center Stage on Day 2 of ASCO Breakthrough 2026 - CancerNetwork

AI and genetic testing for minimal residual disease (traces of cancer) are gaining attention at a major cancer medicine conference. These tools could help doctors better detect whether cancer treatment is working and catch recurrence earlier.